Clinical trial · Observational
Sub-type Specific Genomic Mutations in sBOTs
Sub-type Specific Genomic Mutations in Serous Borderline Ovarian Tumors
NCT03883542CI-TRIAL-00110173active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to identify different origin in carcinogenesis between serous borderline ovarian tumors presenting a. without implants, b. with non-invasive implants, c. with invasive implants and d. with micropapillary pattern. The presence of specific mutations could suggest for a more aggressive primary treatment if a higher risk of recurrence can be expected.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Neoplasm Epithelial | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| genomic mutations study | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- serous BOT
- description
- simple serous BOT ovarian tissue
- interventionNames
- Genetic: genomic mutations study
- label
- serous BOT with non-invasive implants
- description
- BOT ovarian tissue presenting with non-invasive implants
- interventionNames
- Genetic: genomic mutations study
- label
- sBOT with micropapillary grow pattern
- description
- BOT ovarian tissue presenting with micropapillary grow pattern
- interventionNames
- Genetic: genomic mutations study
- label
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Paraffin embedded material from the original borderline ovarian tumor must be present and of good quality for DNA extraction. * Original slides are available for central pathological review. Exclusion Criteria: * Presence of invasive ovarian carcinoma.
References
Publications (4)
- BACKGROUNDMorice P, Uzan C, Fauvet R, Gouy S, Duvillard P, Darai E. Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. Lancet Oncol. 2012 Mar;13(3):e103-15. doi: 10.1016/S1470-2045(11)70288-1. PMID 22381933
- BACKGROUNDVang R, Shih IeM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009 Sep;16(5):267-82. doi: 10.1097/PAP.0b013e3181b4fffa. PMID 19700937
- BACKGROUNDDespierre E, Lambrechts D, Neven P, Amant F, Lambrechts S, Vergote I. The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. Gynecol Oncol. 2010 May;117(2):358-65. doi: 10.1016/j.ygyno.2010.02.012. Epub 2010 Mar 7. PMID 20207398
- BACKGROUNDKurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010 Mar;34(3):433-43. doi: 10.1097/PAS.0b013e3181cf3d79. PMID 20154587